Adding Metformin to the Standard Treatment for Patients With HBeAg-Negative Chronic Hepatitis B
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, placebo-controlled pilot study to assess the efficacy
and safety of adding Metformin to the standard treatment for patients with HBeAg-positive
chronic hepatitis B.